{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T05:05:27Z","timestamp":1768280727280,"version":"3.49.0"},"reference-count":50,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"2","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2021]]},"abstract":"<jats:p>Background: Inflammation is recognized as a hallmark feature of cancer development and progression. The aim of our study was to investigate the significance of serum nuclear factor kappa-B (NF-kB) levels as a circulating marker in the monitoring of inflammation in breast and colon cancer; to show the relationship between NF-kB with inflammatory parameters as tumour necrosis factor-a (TNF-a), soluble TNF-related apoptosis-inducing ligand (sTRAIL), interleukin-6 (IL-6), pentraxin-3 (PTX-3), procalcitonin (PCT), and C-reactive protein (CRP) levels. Methods: Serum NF-kB, TNF-a, sTRAIL, IL-6, PTX-3, PCT, and serum CRP levels were measured using enzyme-linked immunosorbent assay (ELISA) in 40 patients with breast cancer, 40 patients with colon cancer and 30 healthy controls. Results: The serum NF-kB, TNF-a, IL-6, PTX-3, PCT, and serum CRP concentration was significantly higher, and the serum sTRAIL concentration was significantly lower in the patients with breast and colon cancer than in healthy controls. NF-kB was positively correlated with CRP and negatively correlated with sTRAIL. Conclusions: These results suggest that increased NF-kB may decrease the clinical efficacy of sTRAIL in solid tumour cells. There is a relationship between inflammation and carcinogenesis so that the development of cancer occurs with chronic inflammation in breast and colon. The study results have shown that colon and breast cancer patients have increased systemic inflammation, as measured by increased circulating cytokines, and acute-phase proteins, or by abnormalities in circulating cells. NF-kB may combine with other markers of the systemic inflammatory response in prognostic scores in cancer. In addition to surgical resection of the tumour, and conventional radio and chemotherapy for cancer treatment, the use of sTRAIL or other agonists for cancer therapy appeared a new potential therapy.<\/jats:p>","DOI":"10.5937\/jomb0-27128","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T07:59:35Z","timestamp":1600156775000},"page":"150-159","source":"Crossref","is-referenced-by-count":14,"title":["Circulating nuclear factor-kappa B mediates cancer-associated inflammation in human breast and colon cancer"],"prefix":"10.5937","volume":"40","author":[{"suffix":"Berrin","given":"Kundaktepe","family":"Papila","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volkan","family":"Sozer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Pinar","given":"Kocael","family":"Cigdem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinem","family":"Durmus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilara","family":"Kurtulus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cigdem","family":"Papila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remise","family":"Gelisgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafize","family":"Uzun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3964","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-44;","DOI":"10.1038\/nature07205"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"West NR, McCuaig S, Franchini F, Powrie F. Emerging cytokine networks in colorectal cancer. Nat Rev Immunol 2015; 15: 615-29;","DOI":"10.1038\/nri3896"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Hoesel B, Schmid JA. The complexity of NF-B signaling in inflammation and cancer. Mol Cancer 2013; 12: 86;","DOI":"10.1186\/1476-4598-12-86"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Perkins ND. Integrating cell-signalling pathways with NFkappaB and IKK function. Nat Rev Mol Cell Biol 2007; 8: 49-62;","DOI":"10.1038\/nrm2083"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Wu Y, Zhou BP. TNF-alpha\/NF-kappaB\/Snail pathway in cancer cell migration and invasion. Br J Cancer 2010; 102: 639-44;","DOI":"10.1038\/sj.bjc.6605530"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 2011; 48: 155-70;","DOI":"10.3109\/10408363.2011.599831"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Zhou B, Shu B, Yang J, Liu J, Xi T, Xing Y. C-reactive protein, interleukin-6 and the risk of colorectal cancer: a meta-analysis. Cancer Causes Control 2014; 25: 1397-405;","DOI":"10.1007\/s10552-014-0445-8"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Guo L, Liu S, Zhang S, Chen Q, Zhang M, Quan P, Lu J, Sun X. C-reactive protein and risk of breast cancer: A systematic review and meta-analysis. Sci Rep 2015; 5: 10508;","DOI":"10.1038\/srep10508"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Lussana F, Rambaldi A. Inflammation and myeloproliferative neoplasms. J Autoimmun 2017 Dec; 85: 58-63;","DOI":"10.1016\/j.jaut.2017.06.010"},{"key":"ref10","unstructured":"Sbrana A, Torchio M, Comolli G, Antonuzzo A, Danova M; Italian Network for Supportive Care in Oncology (NICSO). Use of procalcitonin in clinical oncology: a literature review. New Microbiol 2016; 39: 174-80;"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"M\u00e9rino D1, Lalaoui N, Morizot A, Solary E, Micheau O. TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets 2007; 11: 1299-314;","DOI":"10.1517\/14728222.11.10.1299"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Prajoko YW, Aryandono T. Expression of nuclear factor kappa B (NF-B) as a predictor of poor pathologic response to chemotherapy in patients with locally advanced breast cancer. Asian Pac J Cancer Prev 2014; 15: 595-8;","DOI":"10.7314\/APJCP.2014.15.2.595"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Coussens LM Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7;","DOI":"10.1038\/nature01322"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Shacter E, Weitzman SA. Chronic Inflammation and Cancer. Oncology 2002; 16: 217-26;","DOI":"10.1016\/S0889-8588(02)00027-8"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 11: 1175-83;","DOI":"10.1172\/JCI31537"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Germano G, Allavena P, Mantovani A. Cytokines as a key component of cancer-related inflammation. Cytokine 2008; 43: 374-9;","DOI":"10.1016\/j.cyto.2008.07.014"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Kim S, Keku TO, Martin C, Galanko J, Woosley JT, Schroeder JC, Satia JA, Halabi S, Sandler RS. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res 2008; 68: 323-8;","DOI":"10.1158\/0008-5472.CAN-07-2924"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich-Rivkin T, Weitzenfeld P, Meshel T, Shabtai E, Gutman M, Ben-Baruch A. Inflammatory mediators in breast cancer: coordinated expression of TNF-a & IL-1 with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 2011; 11: 130;","DOI":"10.1186\/1471-2407-11-130"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, Ganesan TS. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J Clin Oncol 2005; 23: 5950-9;","DOI":"10.1200\/JCO.2005.04.127"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P, Dirix LY. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 2003; 103: 642-6;","DOI":"10.1002\/ijc.10833"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Xu J1, Ye Y, Zhang H, Szmitkowski M, M\u00e4kinen MJ, Li P, Xia D, Yang J, Wu Y, Wu H. Diagnostic and prognostic value of serum \u0131nterleukin-6 in colorectal cancer. Medicine (Baltimore) 2016; 95: e2502;","DOI":"10.1097\/MD.0000000000002502"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Shiga K, Hara M, Nagasaki T, Sato T, Takahashi H, Sato M, Takeyama H. Preoperative Serum Interleukin-6 Is a Potential Prognostic Factor for Colorectal Cancer, including Stage II Patients. Gastroenterol Res Pract 2016; 2016: 9701574;","DOI":"10.1155\/2016\/9701574"},{"key":"ref23","unstructured":"Chung YC, Chaen YL, Hsu CP. Clinical significance of tissue expression of interleukin-6 in colorectal carci - noma. Anticancer Res 2006; 26: 3905-11;"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 1999; 85: 2526-31;","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2526::AID-CNCR6>3.0.CO;2-3"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Chung YC, Chang YF. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 2003; 83: 222-6;","DOI":"10.1002\/jso.10269"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Yeh KY, Li YY, Hsieh LL, Lu CH, Chou WC, Liaw CC, Tang RP, Liao SK. Analysis of the effect of serum interleukin-6 (IL-6) and soluble IL-6 receptor levels on survival of patients with colorectal cancer. Jpn J Clin Oncol 2010; 40: 580-7;","DOI":"10.1093\/jjco\/hyq010"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Berberoglu U, Yildirim E, Celen O. Serum levels of tumor necrosis factor alpha correlate with response to neoadjuvant chemotherapy in locally advanced breast cancer. Int J Biol Markers 2004; 19: 130-4;","DOI":"10.1177\/172460080401900207"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Stanilov N, Miteva L, Dobreva Z, Stanilova S. Colorectal cancer severity and survival in correlation with tumour necrosis factor-alpha. Biotechnol Biotechnol Equip. 2014; 28: 911-7;","DOI":"10.1080\/13102818.2014.965047"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Grimm M, Lazariotou M, Kircher S, H\u00f6felmayr A, Germer CT, von Rahden BHA, Waaga-Gasser AM, Gasser M. Tumor necrosis factor-a is associated with positive lymph node status in patients with recurrence of colorectal cancer -indications for anti-TNF-a agents in cancer treatment. Cell Oncol 2010; 33: 151-63;","DOI":"10.1155\/2010\/891869"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Sharma R, Zucknick M, London R, Kacevska M, Liddle C, Clarke S. Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clin Colorectal Cancer. 2008; 7: 331-7;","DOI":"10.3816\/CCC.2008.n.044"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Tang D, Tao D, Fang Y, Deng C, Xu Q, Zhou J. TNF-Alpha Promotes Invasion and Metastasis via NF-Kappa B Pathway in Oral Squamous Cell Carcinoma. Med Sci Monit Basic Res 2017; 23: 141-9;","DOI":"10.12659\/MSMBR.903910"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-63;","DOI":"10.1038\/5517"},{"key":"ref33","unstructured":"Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA. Preclinical studies to predict the disposition of Apo2L\/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001; 299: 31-8;"},{"key":"ref34","unstructured":"Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 2002; 62: 5800-6;"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Toiyama D, Takaha N, Shinnoh M, Ueda T, Kimura Y, Nakamura T, Hongo F, Mikami K, Kamoi K, Kawauchi A, Miki T. Significance of serum tumor necrosis factor-related apoptosis-inducing ligand as a prognostic biomarker for renal cell carcinoma. Mol Clin Oncol 2013; 1: 69-74;","DOI":"10.3892\/mco.2012.35"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Tecchio C, Huber V, Scapini P, et al. IFN alpha-stimulated neutro-phils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL\/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 2004; 103: 3837-44;","DOI":"10.1182\/blood-2003-08-2806"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Tanaka H, Ito T, Kyo T, Kimura A. Treatment with IFNalpha in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients. Eur J Haematol 2007; 78: 389-98;","DOI":"10.1111\/j.1600-0609.2007.00834.x"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Perik PJ, Van der Graaf WT, De Vries EG, et al. Circulating apoptotic proteins are increased in long-term diseasefree breast cancer survivors. Acta Oncol 2006; 45: 175-83;","DOI":"10.1080\/02841860500482225"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Luo JL, Maeda S, Hsu LC, et al. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 2004; 6: 297-305;","DOI":"10.1016\/j.ccr.2004.08.012"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Kwon HC, Kim SH, Oh SY, Lee S, Kwon KA, Lee JH, Choi HJ, Park KJ, Lee HS, Roh MS, Kim HJ. Clinico - pathological significance of nuclear factor-kappa B, HIF-1 alpha, and vascular endothelial growth factor expression in stage III colorectal cancer. Cancer Sci 2010; 101: 1557-61;","DOI":"10.1111\/j.1349-7006.2010.01553.x"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Slattery ML, Mullany LE, Sakoda L, Samowitz WS, Wolff RK, Stevens JR, Herrick JS. The NF-kB signalling pathway in colorectal cancer: associations between dysregulated gene and miRNA expression. J Cancer Res Clin Oncol 2018; 144: 269-83;","DOI":"10.1007\/s00432-017-2548-6"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Giacomini A, Ghedini GC, Presta M, Ronca R. Long pentraxin 3: a novel multifaceted player in cancer. Biochim Biophys Acta Rev Cancer 2018; 1869: 53-63;","DOI":"10.1016\/j.bbcan.2017.11.004"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Diamandis EP, Goodglick L, Planque C, Thornquist MD. Pentraxin-3 is a novel biomarker of lung carcinoma. Clin Cancer Res 2011; 17: 2395-9;","DOI":"10.1158\/1078-0432.CCR-10-3024"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Choi B, Lee E-J, Song D-H, Yoon S-C, Chung Y-H, Jang Y, et al. Elevated pentraxin 3 in bone metastatic breast cancer is correlated with osteolytic function. Oncotarget 2014; 5: 481-92;","DOI":"10.18632\/oncotarget.1664"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Chen WY, Wu F, You ZY, Zhang ZM, Guo YL, Zhong LX. Analyzing the differentially expressed genes and pathway cross-talk in aggressive breast cancer. J Obstet Gynaecol Res 2015; 41: 132-40;","DOI":"10.1111\/jog.12495"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Player A, Abraham N, Burrell K, Bengone IO, Harris A, Nunez L, et al. Identification of candidate genes associated with triple negative breast cancer. Genes Cancer 2017; 8: 659-72;","DOI":"10.18632\/genesandcancer.147"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Basu S, Harris H, Wolk A, Rossary A, Caldefie-Ch\u00e9zet F, Vasson MP, Larsson A. Inflammatory F2-isoprostane, prostaglandin F2a, pentraxin 3 levels and breast cancer risk: The Swedish Mammography Cohort. Prostaglandins Leukot Essent Fatty Acids 2016; 113: 28-32;","DOI":"10.1016\/j.plefa.2016.08.005"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Zhang J, Wang TY, Niu XC. Increased plasma levels of Pentraxin 3 are associated with poor prognosis of colorectal carcinoma patients. Tohoku J Exp Med 2016; 240: 39-46;","DOI":"10.1620\/tjem.240.39"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Liu B, Zhao Y, Guo L. Increased serum pentraxin-3 level predicts poor prognosis in patients with colorectal cancer after curative surgery, a cohort study. Medicine 2018; 97: e11780;","DOI":"10.1097\/MD.0000000000011780"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Durna B, W tek M, Wollny T, Niemirowicz K, Marzec M, Bucki R, G\u00f3 d S. Utility of blood procalcitonin concentration in the management of cancer patients with infections. Onco Targets Ther 2016; 9: 469-75;","DOI":"10.2147\/OTT.S95600"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Cirkuli\u0161u\u0107i nuklearni faktor kapa-B ukazuje na upale povezane sa rakom u karcinomu dojke i debelog creva"],"language":"en","link":[{"URL":"https:\/\/aseestant.ceon.rs\/index.php\/jomb\/article\/download\/27128\/15883","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2021\/1452-82582102150P.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T10:53:33Z","timestamp":1668768813000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582102150P"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-27128","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}